Notice of Dividend Amount • Mar 27, 2020
Notice of Dividend Amount
Open in ViewerOpens in native device viewer
Annual Report for Medistim ASA for 2019
(Oslo, 27th of March 2020) Medistim ASA (OSE: MEDI), a niche market leader within ultrasound technology with headquarter in Norway, that develops and commercializes medical equipment for use within cardiac, vascular and transplant surgery, announces that the Annual Report for 2019 is approved and available.
With reference to the announcement the 19th of March, the board will reconsider the previously announced dividend of NOK 2.75 per share at the coming Board meeting the 3rd of April, because of uncertainties surrounding the Corona virus situation.
The Board has previously suggested to make a dividend pay-out of NOK 2.75 per share. This was based upon the company’s solid profit and balance sheet with net cash of MNOK 60 by year end 2019, as well as strong outlook for further growth.
While Medistim has a solid balance sheet and very positive long term outlook, it is difficult today to predict how the current Corona virus situation could impact Medistim’s business. The Board has decided to take a cautious approach and reconsider if there is a need to reduce, delay or split a dividend payment. The Board will follow the further development closely, and keep an extraordinary Board meeting on the 3rd of April, in order to make a final decision.
About Medistim:
Medistim was established in 1984, and has a track record of profitable growth over the past >15 years. The company is a pioneer within its segment, and continues to invest in new product development. Medistim has wholly owned subsidiaries with sales organizations in the USA, Germany, UK, Spain, Denmark and Norway, in addition to the about 50 distributors in Europe, Asia, Middle East, Africa, Canada and South America. For more information, visit the Medistim home page: www.Medistim.com
This information is disclosed under Norwegian law (Verdipapirhandelloven §5-12).
For more information, contact:
President and CEO, Kari E. Krogstad, Medistim ASA
Tel: + 47 918 38 110
Email: [email protected]
CFO, Thomas Jakobsen, Medistim ASA
Tel: + 47 906 59 940
Email: [email protected]
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.